Myovant/Pfizer's Relugolix Combo Therapy Shows Sustained Clinical Benefit In Uterine...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 24, 2021 at 10:42: AM
via Myovant Sciences Ltd (NYSE: MYOV) and Pfizer Inc (NYSE: PFE) have announced positive data from the Phase 3 LIBERTY randomized withdrawal study evaluating relugolix combination therapy in women with uterine fibroids.

article source
 

<



Similar threads

cafead
Myovant and Pfizer&#039;s uterine fibroids med scores FDA nod, setting up showdown with AbbVie
Replies
0
Views
204
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Upcoming events – Pfizer&#039;s abrocitinib and Myovant&#039;s relugolix
Replies
0
Views
359
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pfizer and Myovant’s endometriosis pain drug Myfembree gets another FDA nod
Replies
0
Views
274
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Myovant and Pfizer’s path to securing a second nod for Myfembree gets hazy — and investors...
Replies
0
Views
179
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pfizer/Myovant take relugolix contraceptive combination pill into phase 3
Replies
0
Views
114
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote